ID   PTEN_HUMAN              Reviewed;         403 AA.
AC   P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7;
DT   16-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   16-FEB-2004, sequence version 1.
DT   10-MAY-2017, entry version 167.
DE   RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN;
DE            EC=3.1.3.16;
DE            EC=3.1.3.48;
DE            EC=3.1.3.67;
DE   AltName: Full=Mutated in multiple advanced cancers 1;
DE   AltName: Full=Phosphatase and tensin homolog;
GN   Name=PTEN; Synonyms=MMAC1, TEP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RC   TISSUE=Epithelium;
RX   PubMed=9187108;
RA   Li D.M., Sun H.;
RT   "TEP1, encoded by a candidate tumor suppressor locus, is a novel
RT   protein tyrosine phosphatase regulated by transforming growth factor
RT   beta.";
RL   Cancer Res. 57:2124-2129(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANTS GLIOMA SER-15; GLU-36; ARG-42; TRP-57 AND THR-319 DEL.
RX   PubMed=9090379; DOI=10.1038/ng0497-356;
RA   Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A.,
RA   Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T.,
RA   Frye C., Hu R., Swedlund B., Teng D.H.-F., Tavtigian S.V.;
RT   "Identification of a candidate tumour suppressor gene, MMAC1, at
RT   chromosome 10q23.3 that is mutated in multiple advanced cancers.";
RL   Nat. Genet. 15:356-363(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GLIOBLASTOMA
RP   ARG-129 AND PROSTATE CANCER LEU-134.
RX   PubMed=9072974; DOI=10.1126/science.275.5308.1943;
RA   Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J.,
RA   Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C.,
RA   Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R.;
RT   "PTEN, a putative protein tyrosine phosphatase gene mutated in human
RT   brain, breast, and prostate cancer.";
RL   Science 275:1943-1947(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10817502; DOI=10.1054/bjoc.2000.1211;
RA   Hamilton J.A., Stewart L.M.D., Ajayi L., Gray I.C., Gray N.E.,
RA   Roberts K.G., Watson G.J., Kaisary A.V., Snary D.;
RT   "The expression profile for the tumour suppressor gene PTEN and
RT   associated polymorphic markers.";
RL   Br. J. Cancer 82:1671-1676(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Wang S., Li J., Liaw D., Bose S., Podsypanina K., Parsons R.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Jensen K., de la Bastide M., Parsons R., Parnell L.D., Dedhia N.,
RA   Gottesman T., Gnoj L., Kaplan N., Lodhi M., Johnson A.F., Shohdy N.,
RA   Hasegawa A., Haberman K., Huang E.N., Schutz K., Calma C., Granat S.,
RA   Wigler M.H., McCombie W.R.;
RT   "Genomic sequence of PTEN/MMAC1.";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Yang C.-W., Hsu Y.-F.;
RT   "Homo sapiens phosphatase and tensin homolog mRNA splicing variants.";
RL   Submitted (JAN-2011) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Spleen;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-290.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS GLIOMA
RP   TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1
RP   ARG-129; PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER
RP   PRO-167 AND BZ ARG-170.
RX   PubMed=9256433; DOI=10.1073/pnas.94.17.9052;
RA   Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H.,
RA   Parsons R., Tonks N.K.;
RT   "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-
RT   specificity phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997).
RN   [14]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=9593664; DOI=10.1074/jbc.273.22.13375;
RA   Maehama T., Dixon J.E.;
RT   "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second
RT   messenger, phosphatidylinositol 3,4,5-trisphosphate.";
RL   J. Biol. Chem. 273:13375-13378(1998).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ARG-130, AND
RP   CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129.
RX   PubMed=9811831; DOI=10.1073/pnas.95.23.13513;
RA   Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P.,
RA   Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K.;
RT   "The lipid phosphatase activity of PTEN is critical for its tumor
RT   suppressor function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998).
RN   [16]
RP   FUNCTION, MUTAGENESIS OF ASP-92 AND CYS-124, AND CHARACTERIZATION OF
RP   VARIANT GLU-129.
RX   PubMed=9616126; DOI=10.1126/science.280.5369.1614;
RA   Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M.;
RT   "Inhibition of cell migration, spreading, and focal adhesions by tumor
RT   suppressor PTEN.";
RL   Science 280:1614-1617(1998).
RN   [17]
RP   FUNCTION, DOMAIN, AND CHARACTERIZATION OF VARIANTS THR-319 DEL;
RP   GLN-345 AND ILE-348.
RX   PubMed=10468583; DOI=10.1073/pnas.96.18.10182;
RA   Georgescu M.-M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H.;
RT   "The tumor-suppressor activity of PTEN is regulated by its carboxyl-
RT   terminal region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:10182-10187(1999).
RN   [18]
RP   INTERACTION WITH DLG1 AND MAST2, AND PHOSPHORYLATION AT THR-401.
RX   PubMed=10646847;
RA   Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R.,
RA   Byreddy D.V., Tavtigian S.V., Bartel P.L.;
RT   "Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both
RT   inhibits and stimulates PDZ binding.";
RL   Cancer Res. 60:35-37(2000).
RN   [19]
RP   INTERACTION WITH MAGI3.
RX   PubMed=10748157; DOI=10.1074/jbc.M909741199;
RA   Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.;
RT   "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of
RT   MAGI3, a novel membrane-associated guanylate kinase.";
RL   J. Biol. Chem. 275:21477-21485(2000).
RN   [20]
RP   INTERACTION WITH AIP1.
RX   PubMed=10760291; DOI=10.1073/pnas.97.8.4233;
RA   Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.-J.,
RA   Wood J., Ross C., Sawyers C.L., Whang Y.E.;
RT   "Evidence for regulation of the PTEN tumor suppressor by a membrane-
RT   localized multi-PDZ domain containing scaffold protein MAGI-2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:4233-4238(2000).
RN   [21]
RP   PHOSPHORYLATION AT SER-370; SER-380; THR-382; THR-383 AND SER-385.
RX   PubMed=11035045; DOI=10.1074/jbc.M009134200;
RA   Torres J., Pulido R.;
RT   "The tumor suppressor PTEN is phosphorylated by the protein kinase CK2
RT   at its C terminus. Implications for PTEN stability to proteasome-
RT   mediated degradation.";
RL   J. Biol. Chem. 276:993-998(2001).
RN   [22]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH AIP1.
RX   PubMed=11707428; DOI=10.1074/jbc.C100556200;
RA   Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N.,
RA   Sellers W.R.;
RT   "Phosphorylation of the PTEN tail acts as an inhibitory switch by
RT   preventing its recruitment into a protein complex.";
RL   J. Biol. Chem. 276:48627-48630(2001).
RN   [23]
RP   PHOSPHORYLATION AT THR-366; SER-370 AND SER-385.
RX   PubMed=12297295; DOI=10.1016/S0014-5793(02)03274-X;
RA   Miller S., Lou D., Seldin D., Lane W., Neel B.;
RT   "Direct identification of PTEN phosphorylation sites.";
RL   FEBS Lett. 528:145-153(2002).
RN   [24]
RP   INTERACTION WITH STK11, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY
RP   STK11.
RX   PubMed=15987703; DOI=10.1093/hmg/ddi225;
RA   Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A.,
RA   Picard D., Antonarakis S.E.;
RT   "LKB1 interacts with and phosphorylates PTEN: a functional link
RT   between two proteins involved in cancer predisposing syndromes.";
RL   Hum. Mol. Genet. 14:2209-2219(2005).
RN   [25]
RP   INTERACTION WITH MAGI2; MAGI3; MAST1; MAST2 AND MAST3, MUTAGENESIS OF
RP   VAL-403, AND PHOSPHORYLATION.
RX   PubMed=15951562; DOI=10.1074/jbc.M504761200;
RA   Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C.,
RA   Antonarakis S.E., Pulido R.;
RT   "Binding of PTEN to specific PDZ domains contributes to PTEN protein
RT   stability and phosphorylation by microtubule-associated
RT   serine/threonine kinases.";
RL   J. Biol. Chem. 280:28936-28943(2005).
RN   [26]
RP   INTERACTION WITH NEDD4.
RX   PubMed=17218260; DOI=10.1016/j.cell.2006.11.039;
RA   Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z.,
RA   Wang J., Erdjument-Bromage H., Tempst P., Cordon-Cardo C.,
RA   Pandolfi P.P., Jiang X.;
RT   "NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.";
RL   Cell 128:129-139(2007).
RN   [27]
RP   FUNCTION, INTERACTION WITH USP7, UBIQUITINATION AT LYS-13 AND LYS-289,
RP   DEUBIQUITINATION BY USP7, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-13
RP   AND LYS-289, AND CHARACTERIZATION OF VARIANT CWS1 GLU-289.
RX   PubMed=18716620; DOI=10.1038/nature07290;
RA   Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F.,
RA   Teruya-Feldstein J., Pandolfi P.P.;
RT   "The deubiquitinylation and localization of PTEN are regulated by a
RT   HAUSP-PML network.";
RL   Nature 455:813-817(2008).
RN   [28]
RP   INTERACTION WITH FRK, PHOSPHORYLATION AT TYR-336, AND MUTAGENESIS OF
RP   TYR-336.
RX   PubMed=19345329; DOI=10.1016/j.ccr.2009.02.012;
RA   Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B.,
RA   Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.-Y.;
RT   "Rak functions as a tumor suppressor by regulating PTEN protein
RT   stability and function.";
RL   Cancer Cell 15:304-314(2009).
RN   [29]
RP   UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION
RP   WITH XIAP/BIRC4.
RX   PubMed=19473982; DOI=10.1074/jbc.C109.009522;
RA   Van Themsche C., Leblanc V., Parent S., Asselin E.;
RT   "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN
RT   ubiquitination, content, and compartmentalization.";
RL   J. Biol. Chem. 284:20462-20466(2009).
RN   [30]
RP   PHOSPHORYLATION AT THR-366 AND SER-370, AND MUTAGENESIS OF THR-366 AND
RP   SER-370.
RX   PubMed=20940307; DOI=10.1074/jbc.M110.166462;
RA   Xu D., Yao Y., Jiang X., Lu L., Dai W.;
RT   "Regulation of PTEN stability and activity by Plk3.";
RL   J. Biol. Chem. 285:39935-39942(2010).
RN   [31]
RP   INTERACTION WITH NDFIP1 AND NDFIP2.
RX   PubMed=20534535; DOI=10.1073/pnas.0911714107;
RA   Mund T., Pelham H.R.;
RT   "Regulation of PTEN/Akt and MAP kinase signaling pathways by the
RT   ubiquitin ligase activators Ndfip1 and Ndfip2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [33]
RP   FUNCTION IN CELL MIGRATION.
RX   PubMed=22279049; DOI=10.1101/gad.177642.111;
RA   Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H.,
RA   Huttelmaier S.;
RT   "IGF2BP1 promotes cell migration by regulating MK5 and PTEN
RT   signaling.";
RL   Genes Dev. 26:176-189(2012).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [35]
RP   ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, FUNCTION
RP   (ISOFORM ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA).
RX   PubMed=23744781; DOI=10.1126/science.1234907;
RA   Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J.,
RA   Pappas K., Yu J.S., Hodakoski C., Mense S., Klein J., Pegno S.,
RA   Sulis M.L., Goldstein H., Amendolara B., Lei L., Maurer M., Bruce J.,
RA   Canoll P., Hibshoosh H., Parsons R.;
RT   "A secreted PTEN phosphatase that enters cells to alter signaling and
RT   survival.";
RL   Science 341:399-402(2013).
RN   [36]
RP   ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, SUBCELLULAR
RP   LOCATION (ISOFORM ALPHA), AND MUTAGENESIS OF MET-1.
RX   PubMed=24768297; DOI=10.1016/j.cmet.2014.03.023;
RA   Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X.,
RA   McNutt M.A., Shen W.H., Yin Y.;
RT   "PTENalpha, a PTEN isoform translated through alternative initiation,
RT   regulates mitochondrial function and energy metabolism.";
RL   Cell Metab. 19:836-848(2014).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-366, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [38]
RP   INTERACTION WITH NDFIP1, AND SUBCELLULAR LOCATION.
RX   PubMed=25801959; DOI=10.1093/jmcb/mjv020;
RA   Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P.,
RA   Gunnersen J., Silke J., Tan S.S.;
RT   "Ndfip1 represses cell proliferation by controlling Pten localization
RT   and signaling specificity.";
RL   J. Mol. Cell Biol. 7:119-131(2015).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 8-353 IN COMPLEX WITH
RP   L(+)-TARTRATE, SUBUNIT, DOMAIN, AND MUTAGENESIS OF ASP-92; HIS-93;
RP   LYS-125; LYS-128; THR-167; GLN-171; 263-LYS--ALA-269 AND
RP   327-LYS--ALA-335.
RX   PubMed=10555148; DOI=10.1016/S0092-8674(00)81663-3;
RA   Lee J.-O., Yang H., Georgescu M.-M., Di Cristofano A., Maehama T.,
RA   Shi Y., Dixon J.E., Pandolfi P., Pavletich N.P.;
RT   "Crystal structure of the PTEN tumor suppressor: implications for its
RT   phosphoinositide phosphatase activity and membrane association.";
RL   Cell 99:323-334(1999).
RN   [40]
RP   VARIANT CWS1 ASN-137 INS.
RX   PubMed=9345101; DOI=10.1086/301607;
RA   Tsou H.C., Teng D.H.-F., Ping X.L., Brancolini V., Davis T., Hu R.,
RA   Xie X.X., Gruener A.C., Schrager C.A., Christiano A.M., Eng C.,
RA   Steck P., Ott J., Tavtigian S.V., Peacocke M.;
RT   "The role of MMAC1 mutations in early-onset breast cancer: causative
RT   in association with Cowden syndrome and excluded in BRCA1-negative
RT   cases.";
RL   Am. J. Hum. Genet. 61:1036-1043(1997).
RN   [41]
RP   VARIANTS CWS1 GLU-343 AND LEU-347.
RX   PubMed=9399897; DOI=10.1086/301639;
RA   Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J.,
RA   Swisshelm K., Suchard D., MacLeod P.M., Kvinnsland S., Gjertsen B.T.,
RA   Heimdal K., Lubs H., Moeller P., King M.-C.;
RT   "Inherited mutations in PTEN that are associated with breast cancer,
RT   Cowden disease, and juvenile polyposis.";
RL   Am. J. Hum. Genet. 61:1254-1260(1997).
RN   [42]
RP   VARIANTS GLIOBLASTOMA TYR-107; PRO-121; ARG-129; ARG-165 AND GLN-345.
RX   PubMed=9331071;
RA   Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D.,
RA   Parsons R.;
RT   "Somatic mutations of PTEN in glioblastoma multiforme.";
RL   Cancer Res. 57:4183-4186(1997).
RN   [43]
RP   VARIANTS CWS1 ARG-123 AND ARG-124.
RX   PubMed=9259288; DOI=10.1093/hmg/6.8.1383;
RA   Nelen M.R., van Staveren W.C.G., Peeters E.A.J., Ben-Hassel M.,
RA   Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.-P., Sijmons R.H.,
RA   Woods D.G., Mariman E.C.M., Padberg G.W., Kremer H.;
RT   "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden
RT   disease.";
RL   Hum. Mol. Genet. 6:1383-1387(1997).
RN   [44]
RP   VARIANT CWS1 GLU-129.
RX   PubMed=9140396; DOI=10.1038/ng0597-64;
RA   Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z.,
RA   Bose S., Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R.;
RT   "Germline mutations of the PTEN gene in Cowden disease, an inherited
RT   breast and thyroid cancer syndrome.";
RL   Nat. Genet. 16:64-67(1997).
RN   [45]
RP   VARIANT BRRS ARG-170.
RX   PubMed=9241266; DOI=10.1038/ng0897-333;
RA   Marsh D.J., Dahia P.L.M., Zheng Z., Liaw D., Parsons R., Gorlin R.J.,
RA   Eng C.;
RT   "Germline mutations in PTEN are present in Bannayan-Zonana syndrome.";
RL   Nat. Genet. 16:333-334(1997).
RN   [46]
RP   VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND
RP   ILE-348.
RX   PubMed=9635567;
RA   Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C.,
RA   Barrett J.C., Berchuck A., Futreal P.A.;
RT   "Mutation of the PTEN tumor suppressor gene in endometrial
RT   hyperplasias.";
RL   Cancer Res. 58:2500-2503(1998).
RN   [47]
RP   VARIANT CWS1 GLU-289.
RX   PubMed=9797362; DOI=10.1016/S0016-5085(98)70078-2;
RA   Chi S.-G., Kim H.-J., Park B.-J., Min H.-J., Park J.-H., Kim Y.-W.,
RA   Dong S.-H., Kim B.-H., Lee J.-I., Chang Y.-W., Chang R., Kim W.-K.,
RA   Yang M.-H.;
RT   "Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal
RT   polyps in patients with Cowden disease.";
RL   Gastroenterology 115:1084-1089(1998).
RN   [48]
RP   VARIANTS CWS1 HIS-68 AND PRO-112.
RX   PubMed=9600246; DOI=10.1007/s004390050723;
RA   Tsou H.C., Ping X.L., Xie X.X., Gruener A.C., Zhang H., Nini R.,
RA   Swisshelm K., Sybert V., Diamond T.M., Sutphen R., Peacocke M.;
RT   "The genetic basis of Cowden's syndrome: three novel mutations in
RT   PTEN/MMAC1/TEP1.";
RL   Hum. Genet. 102:467-473(1998).
RN   [49]
RP   VARIANTS CWS1 AND BRRS.
RX   PubMed=9467011; DOI=10.1093/hmg/7.3.507;
RA   Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L.M.,
RA   Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.-L.,
RA   Bonnetblanc J.-M., Bressieux J.-M., Cabarrot-Moreau A., Chompret A.,
RA   Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.-P.,
RA   Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Leprat F., Odent S.,
RA   Toulouse C., Olopade O.I., Sobol H., Tishler S., Woods C.G.,
RA   Robinson B.G., Weber H.C., Parsons R., Peacocke M., Longy M., Eng C.;
RT   "Mutation spectrum and genotype-phenotype analyses in Cowden disease
RT   and Bannayan-Zonana syndrome, two hamartoma syndromes with germline
RT   PTEN mutation.";
RL   Hum. Mol. Genet. 7:507-515(1998).
RN   [50]
RP   VARIANT CWS1 TYR-136.
RX   PubMed=9735393;
RA   Scala S., Bruni P., Lo Muzio L., Mignogna M., Viglietto G., Fusco A.;
RT   "Novel mutation of the PTEN gene in an Italian Cowden's disease
RT   kindred.";
RL   Int. J. Oncol. 13:665-668(1998).
RN   [51]
RP   VARIANT CWS1 PRO-70.
RX   PubMed=9832031; DOI=10.1136/jmg.35.11.881;
RA   Marsh D.J., Dahia P.L.M., Caron S., Kum J.B., Frayling I.M.,
RA   Tomlinson I.P.M., Hughes K.S., Eeles R.A., Hodgson S.V., Murday V.A.,
RA   Houlston R., Eng C.;
RT   "Germline PTEN mutations in Cowden syndrome-like families.";
RL   J. Med. Genet. 35:881-885(1998).
RN   [52]
RP   VARIANT CWS1 ARG-35.
RX   PubMed=9425889; DOI=10.1038/ng0198-12;
RA   Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G.;
RT   "PTEN germ-line mutations in juvenile polyposis coli.";
RL   Nat. Genet. 18:12-14(1998).
RN   [53]
RP   VARIANT CWS1 GLN-130.
RX   PubMed=9915974; DOI=10.1086/302207;
RA   Kurose K., Araki T., Matsunaka T., Takada Y., Emi M.;
RT   "Variant manifestation of Cowden disease in Japan: hamartomatous
RT   polyposis of the digestive tract with mutation of the PTEN gene.";
RL   Am. J. Hum. Genet. 64:308-310(1999).
RN   [54]
RP   VARIANT CWS1/LDD PRO-112.
RX   PubMed=10051160;
RX   DOI=10.1002/(SICI)1096-8628(19990212)82:4<290::AID-AJMG3>3.0.CO;2-0;
RA   Sutphen R., Diamond T.M., Minton S.E., Peacocke M., Tsou H.C.,
RA   Root A.W.;
RT   "Severe Lhermitte-Duclos disease with unique germline mutation of
RT   PTEN.";
RL   Am. J. Med. Genet. 82:290-293(1999).
RN   [55]
RP   VARIANTS CWS1 ILE-33 DEL; ARG-123; ARG-124 AND GLU-165.
RX   PubMed=10234502; DOI=10.1038/sj.ejhg.5200289;
RA   Nelen M.R., Kremer H., Konings I.B.M., Schoute F., van Essen A.J.,
RA   Koch R., Woods C.G., Fryns J.-P., Hamel B.C.J., Hoefsloot L.H.,
RA   Peeters E.A.J., Padberg G.W.;
RT   "Novel PTEN mutations in patients with Cowden disease: absence of
RT   clear genotype-phenotype correlations.";
RL   Eur. J. Hum. Genet. 7:267-273(1999).
RN   [56]
RP   VARIANTS BRRS ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246.
RX   PubMed=10400993; DOI=10.1093/hmg/8.8.1461;
RA   Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J.,
RA   Ahmed S.F., Bodurtha J., Crowe C., Curtis M.A., Dasouki M., Dunn T.,
RA   Feit H., Geraghty M.T., Graham J.M. Jr., Hodgson S.V., Hunter A.,
RA   Korf B.R., Manchester D., Miesfeldt S., Murday V.A., Nathanson K.L.,
RA   Parisi M., Pober B., Romano C., Tolmie J.L., Trembath R., Winter R.M.,
RA   Zackai E.H., Zori R.T., Weng L.-P., Dahia P.L.M., Eng C.;
RT   "PTEN mutation spectrum and genotype-phenotype correlations in
RT   Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden
RT   syndrome.";
RL   Hum. Mol. Genet. 8:1461-1472(1999).
RN   [57]
RP   CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61;
RP   HIS-68; CWS1 TYR-71; CWS1 TYR-93; BRRS PHE-105; BRRS TYR-107; PRO-112;
RP   ARG-112; PRO-121; ARG-124; ARG-129; GLU-129; GLY-130; CWS1 LEU-130;
RP   GLN-130; ILE-133; LEU-134; TYR-136; CYS-155; ARG-165; ASN-170;
RP   ARG-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251;
RP   GLU-289; GLY-331; VAL-341; ASN-342; GLU-343; GLN-345; LEU-347; GLY-369
RP   AND ILE-401.
RX   PubMed=10866302;
RA   Han S.-Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S.,
RA   Shiiba K., Matsuno S., Kanamaru R., Ishioka C.;
RT   "Functional evaluation of PTEN missense mutations using in vitro
RT   phosphoinositide phosphatase assay.";
RL   Cancer Res. 60:3147-3151(2000).
RN   [58]
RP   VARIANTS MULTIPLE CANCERS LEU-119 AND LEU-158.
RX   PubMed=10807691; DOI=10.1136/jmg.37.5.336;
RA   De Vivo I., Gertig D.M., Nagase S., Hankinson S.E., O'Brien R.,
RA   Speizer F.E., Parsons R., Hunter D.J.;
RT   "Novel germline mutations in the PTEN tumour suppressor gene found in
RT   women with multiple cancers.";
RL   J. Med. Genet. 37:336-341(2000).
RN   [59]
RP   VARIANTS MALIGNANT MELANOMA ASN-19 AND ILE-217.
RX   PubMed=10978354; DOI=10.1136/jmg.37.9.653;
RA   Celebi J.T., Shendrik I., Silvers D.N., Peacocke M.;
RT   "Identification of PTEN mutations in metastatic melanoma specimens.";
RL   J. Med. Genet. 37:653-657(2000).
RN   [60]
RP   CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129.
RX   PubMed=11230179; DOI=10.1093/hmg/10.6.599;
RA   Weng L.-P., Brown J.L., Eng C.;
RT   "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its
RT   protein phosphatase activity and up-regulating p27 via its lipid
RT   phosphatase activity in a breast cancer model.";
RL   Hum. Mol. Genet. 10:599-604(2001).
RN   [61]
RP   VARIANT VATER ASP-61.
RX   PubMed=11748304; DOI=10.1136/jmg.38.12.820;
RA   Reardon W., Zhou X.-P., Eng C.;
RT   "A novel germline mutation of the PTEN gene in a patient with
RT   macrocephaly, ventricular dilatation, and features of VATER
RT   association.";
RL   J. Med. Genet. 38:820-823(2001).
RN   [62]
RP   VARIANT CWS1 GLY-47, AND VARIANTS BRRS ASP-34; HIS-68; TYR-105;
RP   VAL-135 AND ARG-170.
RX   PubMed=11494117; DOI=10.1038/sj.neo.7900154;
RA   Marsh D.J., Theodosopoulos G., Howell V., Richardson A.-L., Benn D.E.,
RA   Proos A.L., Eng C., Robinson B.G.;
RT   "Rapid mutation scanning of genes associated with familial cancer
RT   syndromes using denaturing high-performance liquid chromatography.";
RL   Neoplasia 3:236-244(2001).
RN   [63]
RP   VARIANT GLM2 GLN-234, AND CHARACTERIZATION OF VARIANT GLM2 GLN-234.
RX   PubMed=12085208; DOI=10.1038/sj.bjc.6600206;
RA   Staal F.J.T., van der Luijt R.B., Baert M.R.M., van Drunen J.,
RA   van Bakel H., Peters E., de Valk I., van Amstel H.K.P.,
RA   Taphoorn M.J.B., Jansen G.H., van Veelen C.W.M., Burgering B.,
RA   Staal G.E.J.;
RT   "A novel germline mutation of PTEN associated with brain tumours of
RT   multiple lineages.";
RL   Br. J. Cancer 86:1586-1591(2002).
RN   [64]
RP   VARIANT HNSCC GLY-121.
RX   PubMed=11801303; DOI=10.1016/S0165-4608(01)00509-X;
RA   Poetsch M., Lorenz G., Kleist B.;
RT   "Detection of new PTEN/MMAC1 mutations in head and neck squamous cell
RT   carcinomas with loss of chromosome 10.";
RL   Cancer Genet. Cytogenet. 132:20-24(2002).
RN   [65]
RP   DISCUSSION OF PTEN INVOLVEMENT IN PROTEUS SYNDROME.
RX   PubMed=12471211; DOI=10.1136/jmg.39.12.937;
RA   Smith J.M., Kirk E.P.E., Theodosopoulos G., Marshall G.M., Walker J.,
RA   Rogers M., Field M., Brereton J.J., Marsh D.J.;
RT   "Germline mutation of the tumour suppressor PTEN in Proteus
RT   syndrome.";
RL   J. Med. Genet. 39:937-940(2002).
RN   [66]
RP   VARIANTS MCEPHAS ARG-93; SER-241 AND GLY-252.
RX   PubMed=15805158; DOI=10.1136/jmg.2004.024646;
RA   Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M.,
RA   Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R.,
RA   Eng C.;
RT   "Subset of individuals with autism spectrum disorders and extreme
RT   macrocephaly associated with germline PTEN tumour suppressor gene
RT   mutations.";
RL   J. Med. Genet. 42:318-321(2005).
RN   [67]
RP   INVOLVEMENT IN CHROMOSOME 10Q23 DELETION SYNDROME.
RX   PubMed=17436248; DOI=10.1086/513607;
RA   Balciuniene J., Feng N., Iyadurai K., Hirsch B., Charnas L.,
RA   Bill B.R., Easterday M.C., Staaf J., Oseth L., Czapansky-Beilman D.,
RA   Avramopoulos D., Thomas G.H., Borg A., Valle D., Schimmenti L.A.,
RA   Selleck S.B.;
RT   "Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated
RT   with cognitive and behavioral abnormalities.";
RL   Am. J. Hum. Genet. 80:938-947(2007).
RN   [68]
RP   VARIANT VAL-132.
RX   PubMed=16752378; DOI=10.1002/ajmg.a.31273;
RA   Tekin M., Hismi B.O., Fitoz S., Yalcinkaya F., Ekim M., Kansu A.,
RA   Ertem M., Deda G., Tutar E., Arsan S., Zhou X.-P., Pilarski R.,
RA   Eng C., Akar N.;
RT   "A germline PTEN mutation with manifestations of prenatal onset and
RT   verrucous epidermal nevus.";
RL   Am. J. Med. Genet. A 140:1472-1475(2006).
RN   [69]
RP   VARIANTS MCEPHAS ILE-131 AND ASN-167.
RX   PubMed=23160955; DOI=10.1126/science.1227764;
RA   O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B.,
RA   Phelps I.G., Carvill G., Kumar A., Lee C., Ankenman K., Munson J.,
RA   Hiatt J.B., Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P.,
RA   Martin B.K., Borenstein E., Nickerson D.A., Mefford H.C., Doherty D.,
RA   Akey J.M., Bernier R., Eichler E.E., Shendure J.;
RT   "Multiplex targeted sequencing identifies recurrently mutated genes in
RT   autism spectrum disorders.";
RL   Science 338:1619-1622(2012).
RN   [70]
RP   VARIANT PROSTATE CANCER GLY-126, CHARACTERIZATION OF VARIANT GLY-126,
RP   MUTAGENESIS OF ALA-126, AND FUNCTION.
RX   PubMed=26504226; DOI=10.1073/pnas.1422504112;
RA   Costa H.A., Leitner M.G., Sos M.L., Mavrantoni A., Rychkova A.,
RA   Johnson J.R., Newton B.W., Yee M.C., De La Vega F.M., Ford J.M.,
RA   Krogan N.J., Shokat K.M., Oliver D., Halaszovich C.R.,
RA   Bustamante C.D.;
RT   "Discovery and functional characterization of a neomorphic PTEN
RT   mutation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:13976-13981(2015).
CC   -!- FUNCTION: Tumor suppressor. Acts as a dual-specificity protein
CC       phosphatase, dephosphorylating tyrosine-, serine- and threonine-
CC       phosphorylated proteins. Also acts as a lipid phosphatase,
CC       removing the phosphate in the D3 position of the inositol ring
CC       from phosphatidylinositol 3,4,5-trisphosphate,
CC       phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-
CC       phosphate and inositol 1,3,4,5-tetrakisphosphate with order of
CC       substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 >
CC       PtdIns3P > Ins(1,3,4,5)P4 (PubMed:26504226). The lipid phosphatase
CC       activity is critical for its tumor suppressor function.
CC       Antagonizes the PI3K-AKT/PKB signaling pathway by
CC       dephosphorylating phosphoinositides and thereby modulating cell
CC       cycle progression and cell survival. The unphosphorylated form
CC       cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates
CC       tyrosine-phosphorylated focal adhesion kinase and inhibits cell
CC       migration and integrin-mediated cell spreading and focal adhesion
CC       formation. Plays a role as a key modulator of the AKT-mTOR
CC       signaling pathway controlling the tempo of the process of newborn
CC       neurons integration during adult neurogenesis, including correct
CC       neuron positioning, dendritic development and synapse formation.
CC       May be a negative regulator of insulin signaling and glucose
CC       metabolism in adipose tissue. The nuclear monoubiquitinated form
CC       possesses greater apoptotic potential, whereas the cytoplasmic
CC       nonubiquitinated form induces less tumor suppressive ability. In
CC       motile cells, suppresses the formation of lateral pseudopods and
CC       thereby promotes cell polarization and directed movement.
CC       {ECO:0000269|PubMed:26504226}.
CC   -!- FUNCTION: Isoform alpha: Functional kinase, like isoform 1 it
CC       antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in
CC       mitochondrial energetic metabolism by promoting COX activity and
CC       ATP production, via collaboration with isoform 1 in increasing
CC       protein levels of PINK1.
CC   -!- CATALYTIC ACTIVITY: Phosphatidylinositol 3,4,5-trisphosphate +
CC       H(2)O = phosphatidylinositol 4,5-bisphosphate + phosphate.
CC   -!- CATALYTIC ACTIVITY: [a protein]-serine/threonine phosphate + H(2)O
CC       = [a protein]-serine/threonine + phosphate.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the
CC       second PDZ domain of AIP1 and with DLG1 and MAST2 in vitro
CC       (PubMed:10646847, PubMed:10760291, PubMed:11707428). Interacts
CC       with MAGI2, MAGI3, MAST1 and MAST3, but neither with MAST4 nor
CC       with DLG5; interaction with MAGI2 increases protein stability
CC       (PubMed:10748157, PubMed:15951562). Interacts with NEDD4
CC       (PubMed:17218260). Interacts with NDFIP1 and NDFIP2; in the
CC       presence of NEDD4 or ITCH, this interaction promotes PTEN
CC       ubiquitination (PubMed:25801959, PubMed:20534535). Interacts (via
CC       C2 domain) with FRK (PubMed:19345329). Interacts with USP7; the
CC       interaction is direct (PubMed:18716620). Interacts with ROCK1 (By
CC       similarity). Interacts with XIAP/BIRC4 (PubMed:19473982).
CC       Interacts with STK11; the interaction phosphorylates PTEN
CC       (PubMed:15987703). {ECO:0000250|UniProtKB:O08586,
CC       ECO:0000269|PubMed:10555148, ECO:0000269|PubMed:10646847,
CC       ECO:0000269|PubMed:10748157, ECO:0000269|PubMed:10760291,
CC       ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15951562,
CC       ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:17218260,
CC       ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19345329,
CC       ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:20534535,
CC       ECO:0000269|PubMed:25801959}.
CC   -!- INTERACTION:
CC       Self; NbExp=9; IntAct=EBI-696162, EBI-696162;
CC       P35226:BMI1; NbExp=3; IntAct=EBI-696162, EBI-2341576;
CC       P30260:CDC27; NbExp=7; IntAct=EBI-696162, EBI-994813;
CC       Q16643:DBN1; NbExp=5; IntAct=EBI-696162, EBI-351394;
CC       Q62696:Dlg1 (xeno); NbExp=2; IntAct=EBI-696162, EBI-389325;
CC       P42685:FRK; NbExp=7; IntAct=EBI-696162, EBI-1383583;
CC       O88382:Magi2 (xeno); NbExp=3; IntAct=EBI-696162, EBI-696179;
CC       Q9JK71:Magi3 (xeno); NbExp=3; IntAct=EBI-696162, EBI-696226;
CC       Q9R1L5:Mast1 (xeno); NbExp=3; IntAct=EBI-696162, EBI-491771;
CC       Q60592:Mast2 (xeno); NbExp=4; IntAct=EBI-696162, EBI-493888;
CC       O60307:MAST3; NbExp=3; IntAct=EBI-696162, EBI-311420;
CC       Q9Y6Q9:NCOA3; NbExp=2; IntAct=EBI-696162, EBI-81196;
CC       P46934:NEDD4; NbExp=4; IntAct=EBI-696162, EBI-726944;
CC       P09619:PDGFRB; NbExp=3; IntAct=EBI-696162, EBI-641237;
CC       P62136:PPP1CA; NbExp=2; IntAct=EBI-696162, EBI-357253;
CC       Q06830:PRDX1; NbExp=7; IntAct=EBI-696162, EBI-353193;
CC       O14745:SLC9A3R1; NbExp=7; IntAct=EBI-696162, EBI-349787;
CC       Q15599:SLC9A3R2; NbExp=5; IntAct=EBI-696162, EBI-1149760;
CC       Q9JHL1:Slc9a3r2 (xeno); NbExp=2; IntAct=EBI-696162, EBI-538451;
CC       O43791:SPOP; NbExp=4; IntAct=EBI-696162, EBI-743549;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15987703,
CC       ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982,
CC       ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:9187108}. Nucleus
CC       {ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:25801959}.
CC       Nucleus, PML body {ECO:0000269|PubMed:18716620}.
CC       Note=Monoubiquitinated form is nuclear. Nonubiquitinated form is
CC       cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies
CC       (PubMed:18716620). XIAP/BIRC4 promotes its nuclear localization
CC       (PubMed:19473982). {ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:19473982}.
CC   -!- SUBCELLULAR LOCATION: Isoform alpha: Secreted
CC       {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}.
CC       Note=May be secreted via a classical signal peptide and reenter
CC       into cells with the help of a poly-Arg motif.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=3;
CC       Name=1; Synonyms=55kDa;
CC         IsoId=P60484-1; Sequence=Displayed;
CC       Name=alpha; Synonyms=70kDa, PTEN-long;
CC         IsoId=P60484-2; Sequence=VSP_055420;
CC         Note=Produced by alternative initiation at a CTG start codon of
CC         isoform 1. May contain a signal peptide at positions 1-21.;
CC       Name=3;
CC         IsoId=P60484-3; Sequence=VSP_055421, VSP_055422, VSP_055423;
CC   -!- TISSUE SPECIFICITY: Expressed at a relatively high level in all
CC       adult tissues, including heart, brain, placenta, lung, liver,
CC       muscle, kidney and pancreas. {ECO:0000269|PubMed:9090379}.
CC   -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:9187108}.
CC   -!- DOMAIN: The C2 domain binds phospholipid membranes in vitro in a
CC       Ca(2+)-independent manner; this binding is important for its tumor
CC       suppressor function. {ECO:0000269|PubMed:10468583,
CC       ECO:0000269|PubMed:10555148}.
CC   -!- PTM: Constitutively phosphorylated by CK2 under normal conditions.
CC       Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11.
CC       Phosphorylation results in an inhibited activity towards PIP3.
CC       Phosphorylation can both inhibit or promote PDZ-binding.
CC       Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from
CC       ubiquitin-mediated degradation probably by inhibiting its binding
CC       to NEDD4. Phosphorylation by ROCK1 is essential for its stability
CC       and activity. Phosphorylation by PLK3 promotes its stability and
CC       prevents its degradation by the proteasome.
CC       {ECO:0000269|PubMed:10646847, ECO:0000269|PubMed:11035045,
CC       ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:12297295,
CC       ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703,
CC       ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19345329,
CC       ECO:0000269|PubMed:20940307}.
CC   -!- PTM: Monoubiquitinated; monoubiquitination is increased in
CC       presence of retinoic acid. Deubiquitinated by USP7; leading to its
CC       nuclear exclusion. Monoubiquitination of one of either Lys-13 and
CC       Lys-289 amino acid is sufficient to modulate PTEN
CC       compartmentalization. Ubiquitinated by XIAP/BIRC4.
CC       {ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982}.
CC   -!- DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal
CC       dominant hamartomatous polyposis syndrome with age-related
CC       penetrance. Cowden syndrome is characterized by hamartomatous
CC       lesions affecting derivatives of ectodermal, mesodermal and
CC       endodermal layers, macrocephaly, facial trichilemmomas (benign
CC       tumors of the hair follicle infundibulum), acral keratoses,
CC       papillomatous papules, and elevated risk for development of
CC       several types of malignancy, particularly breast carcinoma in
CC       women and thyroid carcinoma in both men and women. Colon cancer
CC       and renal cell carcinoma have also been reported. Hamartomas can
CC       be found in virtually every organ, but most commonly in the skin,
CC       gastrointestinal tract, breast and thyroid.
CC       {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502,
CC       ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:11494117,
CC       ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:9140396,
CC       ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101,
CC       ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889,
CC       ECO:0000269|PubMed:9467011, ECO:0000269|PubMed:9600246,
CC       ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362,
CC       ECO:0000269|PubMed:9811831, ECO:0000269|PubMed:9832031,
CC       ECO:0000269|PubMed:9915974}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare
CC       disease characterized by the occurrence of a slowly enlarging mass
CC       within the cerebellar cortex corresponding histologically to a
CC       cerebellar hamartoma. It manifests, most commonly in the third and
CC       fourth decades of life, with increased intracranial pressure,
CC       headache, nausea, cerebellar dysfunction, occlusive hydrocephalus,
CC       ataxia, visual disturbances and other cranial nerve palsies.
CC       Various associated abnormalities may be present such as
CC       megalencephaly, microgyria, hydromyelia, polydactyly, partial
CC       gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor
CC       syndromes spectrum that also includes Cowden syndrome. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Bannayan-Riley-Ruvalcaba syndrome (BRRS) [MIM:153480]: A
CC       rare hamartomatous disorder characterized by macrocephaly and
CC       multiple hemangiomas as well as subcutaneous and visceral lipomas.
CC       It belongs to the family of hamartomatous polyposis syndromes that
CC       includes Peutz Jeghers syndrome, juvenile polyposis, and Cowden
CC       syndrome. {ECO:0000269|PubMed:10400993,
CC       ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:9241266,
CC       ECO:0000269|PubMed:9467011}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC)
CC       [MIM:275355]: A non-melanoma skin cancer affecting the head and
CC       neck. The hallmark of cutaneous SCC is malignant transformation of
CC       normal epidermal keratinocytes. {ECO:0000269|PubMed:11801303}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of
CC       endometrium, the mucous lining of the uterus. Most endometrial
CC       cancers are adenocarcinomas, cancers that begin in cells that make
CC       and release mucus and other fluids. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=PTEN mutations are found in a subset of patients
CC       with Proteus syndrome, a genetically heterogeneous condition. The
CC       molecular diagnosis of PTEN mutation positive cases classifies
CC       Proteus syndrome patients as part of the PTEN hamartoma syndrome
CC       spectrum. As such, patients surviving the early years of Proteus
CC       syndrome are likely at a greater risk of developing malignancies.
CC   -!- DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or
CC       malignant central nervous system neoplasms derived from glial
CC       cells. They comprise astrocytomas and glioblastoma multiforme that
CC       are derived from astrocytes, oligodendrogliomas derived from
CC       oligodendrocytes and ependymomas derived from ependymocytes.
CC       {ECO:0000269|PubMed:12085208}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: VACTERL association with hydrocephalus (VACTERL-H)
CC       [MIM:276950]: VACTERL is an acronym for vertebral anomalies, anal
CC       atresia, congenital cardiac disease, tracheoesophageal fistula,
CC       renal anomalies, radial dysplasia, and other limb defects.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy
CC       originating in tissues of the prostate. Most prostate cancers are
CC       adenocarcinomas that develop in the acini of the prostatic ducts.
CC       Other rare histopathologic types of prostate cancer that occur in
CC       approximately 5% of patients include small cell carcinoma,
CC       mucinous carcinoma, prostatic ductal carcinoma, transitional cell
CC       carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid
CC       cystic carcinoma (basaloid), signet-ring cell carcinoma and
CC       neuroendocrine carcinoma. {ECO:0000269|PubMed:26504226,
CC       ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]:
CC       Patients have autism spectrum disorders and macrocephaly, with
CC       head circumferences ranging from +2.5 to +8 SD for age and sex
CC       (average head circumference +4.0 SD).
CC       {ECO:0000269|PubMed:15805158, ECO:0000269|PubMed:23160955}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A
CC       and PTEN is a cause of chromosome 10q23 deletion syndrome, which
CC       shows overlapping features of the following three disorders:
CC       Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis
CC       syndrome.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PTENID158.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pten/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U96180; AAB66902.1; -; mRNA.
DR   EMBL; U92436; AAC51182.1; -; mRNA.
DR   EMBL; U93051; AAC51183.1; -; mRNA.
DR   EMBL; AF143315; AAD38372.1; -; Genomic_DNA.
DR   EMBL; AF143312; AAD38372.1; JOINED; Genomic_DNA.
DR   EMBL; AF143313; AAD38372.1; JOINED; Genomic_DNA.
DR   EMBL; AF143314; AAD38372.1; JOINED; Genomic_DNA.
DR   EMBL; AF000734; AAC08699.1; -; Genomic_DNA.
DR   EMBL; AF000726; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000727; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000728; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000729; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000730; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000731; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000732; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000733; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF067844; AAD13528.1; -; Genomic_DNA.
DR   EMBL; JF268690; ADZ48535.1; -; mRNA.
DR   EMBL; CR450306; CAG29302.1; -; mRNA.
DR   EMBL; AK313581; BAG36351.1; -; mRNA.
DR   EMBL; DQ073384; AAY57327.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW50174.1; -; Genomic_DNA.
DR   EMBL; BC005821; AAH05821.1; -; mRNA.
DR   CCDS; CCDS31238.1; -. [P60484-1]
DR   RefSeq; NP_000305.3; NM_000314.6. [P60484-1]
DR   RefSeq; NP_001291646.2; NM_001304717.2.
DR   RefSeq; NP_001291647.1; NM_001304718.1.
DR   UniGene; Hs.500466; -.
DR   UniGene; Hs.729457; -.
DR   PDB; 1D5R; X-ray; 2.10 A; A=8-353.
DR   PDB; 2KYL; NMR; -; B=391-403.
DR   PDB; 4O1V; X-ray; 2.00 A; B=354-368.
DR   PDB; 5BUG; X-ray; 2.40 A; A/B/C/D=14-351.
DR   PDB; 5BZX; X-ray; 2.50 A; A/B/C/D=14-351.
DR   PDB; 5BZZ; X-ray; 2.20 A; A/B/C/D=14-351.
DR   PDBsum; 1D5R; -.
DR   PDBsum; 2KYL; -.
DR   PDBsum; 4O1V; -.
DR   PDBsum; 5BUG; -.
DR   PDBsum; 5BZX; -.
DR   PDBsum; 5BZZ; -.
DR   ProteinModelPortal; P60484; -.
DR   SMR; P60484; -.
DR   BioGrid; 111700; 261.
DR   DIP; DIP-35019N; -.
DR   IntAct; P60484; 52.
DR   MINT; MINT-127351; -.
DR   STRING; 9606.ENSP00000361021; -.
DR   BindingDB; P60484; -.
DR   ChEMBL; CHEMBL2052032; -.
DR   GuidetoPHARMACOLOGY; 2497; -.
DR   SwissLipids; SLP:000000849; -.
DR   DEPOD; P60484; -.
DR   iPTMnet; P60484; -.
DR   PhosphoSitePlus; P60484; -.
DR   BioMuta; PTEN; -.
DR   DMDM; 42560209; -.
DR   EPD; P60484; -.
DR   MaxQB; P60484; -.
DR   PaxDb; P60484; -.
DR   PeptideAtlas; P60484; -.
DR   PRIDE; P60484; -.
DR   DNASU; 5728; -.
DR   Ensembl; ENST00000371953; ENSP00000361021; ENSG00000171862. [P60484-1]
DR   GeneID; 5728; -.
DR   KEGG; hsa:5728; -.
DR   UCSC; uc001kfb.4; human. [P60484-1]
DR   CTD; 5728; -.
DR   DisGeNET; 5728; -.
DR   GeneCards; PTEN; -.
DR   GeneReviews; PTEN; -.
DR   HGNC; HGNC:9588; PTEN.
DR   HPA; CAB004076; -.
DR   HPA; HPA031335; -.
DR   MalaCards; PTEN; -.
DR   MIM; 137800; phenotype.
DR   MIM; 153480; phenotype.
DR   MIM; 158350; phenotype.
DR   MIM; 176807; phenotype.
DR   MIM; 275355; phenotype.
DR   MIM; 276950; phenotype.
DR   MIM; 601728; gene.
DR   MIM; 605309; phenotype.
DR   MIM; 608089; phenotype.
DR   MIM; 612242; phenotype.
DR   MIM; 613028; phenotype.
DR   neXtProt; NX_P60484; -.
DR   OpenTargets; ENSG00000171862; -.
DR   Orphanet; 109; Bannayan-Riley-Ruvalcaba syndrome.
DR   Orphanet; 201; Cowden syndrome.
DR   Orphanet; 145; Hereditary breast and ovarian cancer syndrome.
DR   Orphanet; 79076; Juvenile polyposis of infancy.
DR   Orphanet; 65285; Lhermitte-Duclos disease.
DR   Orphanet; 210548; Macrocephaly-autism syndrome.
DR   Orphanet; 744; Proteus syndrome.
DR   Orphanet; 2969; Proteus-like syndrome.
DR   Orphanet; 137608; Segmental outgrowth - lipomatosis - arteriovenous malformation - epidermal nevus.
DR   Orphanet; 67037; Squamous cell carcinoma of head and neck.
DR   PharmGKB; PA33942; -.
DR   eggNOG; KOG2283; Eukaryota.
DR   eggNOG; COG2453; LUCA.
DR   GeneTree; ENSGT00760000119113; -.
DR   HOGENOM; HOG000008008; -.
DR   HOVERGEN; HBG000239; -.
DR   InParanoid; P60484; -.
DR   KO; K01110; -.
DR   OMA; YSPCESD; -.
DR   OrthoDB; EOG091G09VG; -.
DR   PhylomeDB; P60484; -.
DR   TreeFam; TF324513; -.
DR   BioCyc; MetaCyc:HS10404-MONOMER; -.
DR   BRENDA; 3.1.3.16; 2681.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   SignaLink; P60484; -.
DR   SIGNOR; P60484; -.
DR   ChiTaRS; PTEN; human.
DR   EvolutionaryTrace; P60484; -.
DR   GeneWiki; PTEN_(gene); -.
DR   GenomeRNAi; 5728; -.
DR   PMAP-CutDB; P60484; -.
DR   PRO; PR:P60484; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000171862; -.
DR   CleanEx; HS_PTEN; -.
DR   CleanEx; HS_TEP1; -.
DR   ExpressionAtlas; P60484; baseline and differential.
DR   Genevisible; P60484; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IMP:UniProtKB.
DR   GO; GO:0042995; C:cell projection; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0035749; C:myelin sheath adaxonal region; ISS:BHF-UCL.
DR   GO; GO:0043005; C:neuron projection; ISS:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:BHF-UCL.
DR   GO; GO:0010997; F:anaphase-promoting complex binding; IPI:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB.
DR   GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004438; F:phosphatidylinositol-3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:BHF-UCL.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0008138; F:protein tyrosine/serine/threonine phosphatase activity; IEA:InterPro.
DR   GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:MGI.
DR   GO; GO:0030534; P:adult behavior; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; ISS:UniProtKB.
DR   GO; GO:0048854; P:brain morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0048738; P:cardiac muscle tissue development; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; ISS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0071257; P:cellular response to electrical stimulus; IMP:BHF-UCL.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; ISS:UniProtKB.
DR   GO; GO:0032286; P:central nervous system myelin maintenance; ISS:BHF-UCL.
DR   GO; GO:0021955; P:central nervous system neuron axonogenesis; ISS:BHF-UCL.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0021542; P:dentate gyrus development; ISS:BHF-UCL.
DR   GO; GO:0043542; P:endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0046855; P:inositol phosphate dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0007611; P:learning or memory; ISS:BHF-UCL.
DR   GO; GO:0045475; P:locomotor rhythm; ISS:BHF-UCL.
DR   GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL.
DR   GO; GO:0060292; P:long term synaptic depression; IEA:Ensembl.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0060179; P:male mating behavior; IEA:Ensembl.
DR   GO; GO:0042711; P:maternal behavior; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0033555; P:multicellular organismal response to stress; ISS:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0048681; P:negative regulation of axon regeneration; IEA:Ensembl.
DR   GO; GO:0050771; P:negative regulation of axonogenesis; ISS:BHF-UCL.
DR   GO; GO:0060044; P:negative regulation of cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0090344; P:negative regulation of cell aging; IEA:Ensembl.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045792; P:negative regulation of cell size; ISS:BHF-UCL.
DR   GO; GO:0031658; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0061002; P:negative regulation of dendritic spine morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:BHF-UCL.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:UniProtKB.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0051548; P:negative regulation of keratinocyte migration; IMP:BHF-UCL.
DR   GO; GO:0031642; P:negative regulation of myelination; IEA:Ensembl.
DR   GO; GO:0046621; P:negative regulation of organ growth; ISS:BHF-UCL.
DR   GO; GO:0050765; P:negative regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:0014067; P:negative regulation of phosphatidylinositol 3-kinase signaling; TAS:BHF-UCL.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0090071; P:negative regulation of ribosome biogenesis; IEA:Ensembl.
DR   GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; ISS:BHF-UCL.
DR   GO; GO:1903690; P:negative regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL.
DR   GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL.
DR   GO; GO:2000060; P:positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:1903984; P:positive regulation of TRAIL-activated apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:1904668; P:positive regulation of ubiquitin protein ligase activity; IDA:BHF-UCL.
DR   GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL.
DR   GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL.
DR   GO; GO:0097105; P:presynaptic membrane assembly; ISS:BHF-UCL.
DR   GO; GO:0060736; P:prostate gland growth; IEA:Ensembl.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0043491; P:protein kinase B signaling; ISS:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL.
DR   GO; GO:0002902; P:regulation of B cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0032535; P:regulation of cellular component size; ISS:BHF-UCL.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; TAS:UniProtKB.
DR   GO; GO:0033032; P:regulation of myeloid cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl.
DR   GO; GO:0033198; P:response to ATP; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0010043; P:response to zinc ion; IEA:Ensembl.
DR   GO; GO:0060024; P:rhythmic synaptic transmission; ISS:BHF-UCL.
DR   GO; GO:0035176; P:social behavior; ISS:BHF-UCL.
DR   GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL.
DR   GO; GO:0060074; P:synapse maturation; ISS:BHF-UCL.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR000340; Dual-sp_phosphatase_cat-dom.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR014020; Tensin_C2-dom.
DR   InterPro; IPR029023; Tensin_phosphatase.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   Pfam; PF00782; DSPc; 1.
DR   Pfam; PF10409; PTEN_C2; 1.
DR   PIRSF; PIRSF038025; PTEN; 1.
DR   SMART; SM01326; PTEN_C2; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   PROSITE; PS51182; C2_TENSIN; 1.
DR   PROSITE; PS51181; PPASE_TENSIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation;
KW   Alternative splicing; Apoptosis; Autism spectrum disorder;
KW   Complete proteome; Cytoplasm; Disease mutation; Hydrolase;
KW   Isopeptide bond; Lipid metabolism; Lipid-binding; Neurogenesis;
KW   Nucleus; Phosphoprotein; Polymorphism; Protein phosphatase;
KW   Reference proteome; Secreted; Tumor suppressor; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    403       Phosphatidylinositol 3,4,5-trisphosphate
FT                                3-phosphatase and dual-specificity
FT                                protein phosphatase PTEN.
FT                                /FTId=PRO_0000215904.
FT   DOMAIN       14    185       Phosphatase tensin-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00590}.
FT   DOMAIN      190    350       C2 tensin-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00589}.
FT   REGION      401    403       PDZ domain-binding.
FT   ACT_SITE    124    124       Phosphocysteine intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00590}.
FT   MOD_RES       2      2       N-acetylthreonine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES     294    294       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O08586}.
FT   MOD_RES     336    336       Phosphotyrosine; by FRK.
FT                                {ECO:0000269|PubMed:19345329}.
FT   MOD_RES     366    366       Phosphothreonine; by GSK3-beta and PLK3.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:12297295,
FT                                ECO:0000269|PubMed:20940307}.
FT   MOD_RES     370    370       Phosphoserine; by CK2 and PLK3.
FT                                {ECO:0000269|PubMed:11035045,
FT                                ECO:0000269|PubMed:12297295,
FT                                ECO:0000269|PubMed:20940307}.
FT   MOD_RES     380    380       Phosphoserine; by ROCK1 and CK2.
FT                                {ECO:0000269|PubMed:11035045}.
FT   MOD_RES     382    382       Phosphothreonine; by ROCK1 and CK2.
FT                                {ECO:0000269|PubMed:11035045}.
FT   MOD_RES     383    383       Phosphothreonine; by ROCK1 and CK2.
FT                                {ECO:0000269|PubMed:11035045}.
FT   MOD_RES     385    385       Phosphoserine; by CK2.
FT                                {ECO:0000269|PubMed:11035045,
FT                                ECO:0000269|PubMed:12297295}.
FT   MOD_RES     401    401       Phosphothreonine.
FT                                {ECO:0000269|PubMed:10646847}.
FT   CROSSLNK     13     13       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:18716620}.
FT   CROSSLNK    289    289       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:18716620}.
FT   VAR_SEQ       1      1       M -> MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGE
FT                                LVSPLLLPPTRRRRRRHIQGPGPVLNLPSAAAAPPVARAPE
FT                                AAGGGSRSEDYSSSPHSAAAAARPLAAEEKQAQSLQPSSSR
FT                                RSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLL
FT                                PSLSSFFFSHRLPDM (in isoform alpha).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_055420.
FT   VAR_SEQ      55     70       RFLDSKHKNHYKIYNL -> S (in isoform 3).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_055421.
FT   VAR_SEQ     165    190       GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKG
FT                                IIVIGDGSSMDVIAP (in isoform 3).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_055422.
FT   VAR_SEQ     191    403       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_055423.
FT   VARIANT      10     10       S -> N (retains phosphatase activity
FT                                towards Ins(1,3,4,5)P4 and
FT                                PtdIns(3,4,5)P3; retains the ability to
FT                                bind phospholipid membranes).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026248.
FT   VARIANT      15     15       R -> S (in glioma).
FT                                {ECO:0000269|PubMed:9090379}.
FT                                /FTId=VAR_007457.
FT   VARIANT      16     16       Y -> C (loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P4; retains the
FT                                ability to bind phospholipid membranes).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026249.
FT   VARIANT      19     19       D -> N (in malignant melanoma; somatic
FT                                mutation; dbSNP:rs121909233).
FT                                {ECO:0000269|PubMed:10978354}.
FT                                /FTId=VAR_018100.
FT   VARIANT      20     20       G -> E (reduced phosphatase activity
FT                                towards Ins(1,3,4,5)P4; retains
FT                                phosphatase activity towards
FT                                PtdIns(3,4,5)P3).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026250.
FT   VARIANT      27     27       Y -> S (loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P4).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026251.
FT   VARIANT      33     33       Missing (in CWS1).
FT                                {ECO:0000269|PubMed:10234502}.
FT                                /FTId=VAR_008733.
FT   VARIANT      34     34       A -> D (in BRRS).
FT                                {ECO:0000269|PubMed:10400993,
FT                                ECO:0000269|PubMed:11494117}.
FT                                /FTId=VAR_008734.
FT   VARIANT      35     35       M -> R (in CWS1; dbSNP:rs121909225).
FT                                {ECO:0000269|PubMed:9425889}.
FT                                /FTId=VAR_008036.
FT   VARIANT      36     36       G -> E (in glioma).
FT                                {ECO:0000269|PubMed:9090379}.
FT                                /FTId=VAR_007458.
FT   VARIANT      36     36       G -> R (in endometrial hyperplasia;
FT                                dbSNP:rs786204854).
FT                                {ECO:0000269|PubMed:9635567}.
FT                                /FTId=VAR_026252.
FT   VARIANT      42     42       L -> R (in glioma; retains phosphatase
FT                                activity towards Ins(1,3,4,5)P4 and
FT                                PtdIns(3,4,5)P3; retains the ability to
FT                                bind phospholipid membranes).
FT                                {ECO:0000269|PubMed:9090379}.
FT                                /FTId=VAR_007459.
FT   VARIANT      47     47       R -> G (in CWS1; dbSNP:rs786204855).
FT                                {ECO:0000269|PubMed:11494117}.
FT                                /FTId=VAR_011587.
FT   VARIANT      57     57       L -> W (in glioma; loss of protein
FT                                phosphatase activity; dbSNP:rs786202398).
FT                                {ECO:0000269|PubMed:9090379,
FT                                ECO:0000269|PubMed:9256433}.
FT                                /FTId=VAR_007460.
FT   VARIANT      61     61       H -> D (in VATER; dbSNP:rs121909236).
FT                                {ECO:0000269|PubMed:11748304}.
FT                                /FTId=VAR_018101.
FT   VARIANT      61     61       H -> R (loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P4;
FT                                dbSNP:rs398123316).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026253.
FT   VARIANT      67     67       I -> R (in CWS1).
FT                                /FTId=VAR_007461.
FT   VARIANT      68     68       Y -> H (in CWS1 and BRRS; loss of
FT                                phosphatase activity towards
FT                                Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3;
FT                                retains the ability to bind phospholipid
FT                                membranes; dbSNP:rs398123317).
FT                                {ECO:0000269|PubMed:10400993,
FT                                ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:11494117,
FT                                ECO:0000269|PubMed:9600246}.
FT                                /FTId=VAR_007462.
FT   VARIANT      70     70       L -> P (in CWS1; dbSNP:rs121909226).
FT                                {ECO:0000269|PubMed:9832031}.
FT                                /FTId=VAR_018102.
FT   VARIANT      71     71       C -> Y (in CWS1; loss of phosphatase
FT                                activity towards Ins(1,3,4,5)P4).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026254.
FT   VARIANT      93     93       H -> R (in MCEPHAS; dbSNP:rs121909238).
FT                                {ECO:0000269|PubMed:15805158}.
FT                                /FTId=VAR_032634.
FT   VARIANT      93     93       H -> Y (in CWS1).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026255.
FT   VARIANT     105    105       C -> F (in BRRS; loss of phosphatase
FT                                activity towards Ins(1,3,4,5)P4).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026256.
FT   VARIANT     105    105       C -> Y (in BRRS; dbSNP:rs587782343).
FT                                {ECO:0000269|PubMed:10400993,
FT                                ECO:0000269|PubMed:11494117}.
FT                                /FTId=VAR_008735.
FT   VARIANT     107    107       D -> Y (in BRRS and glioblastoma; loss of
FT                                phosphatase activity towards
FT                                Ins(1,3,4,5)P4).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9331071}.
FT                                /FTId=VAR_026257.
FT   VARIANT     112    112       L -> P (in CWS1 and LDD; loss of
FT                                phosphatase activity towards
FT                                Ins(1,3,4,5)P4; dbSNP:rs121909230).
FT                                {ECO:0000269|PubMed:10051160,
FT                                ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9600246}.
FT                                /FTId=VAR_007807.
FT   VARIANT     112    112       L -> R (loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P4).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026258.
FT   VARIANT     119    119       V -> L (in multiple cancers;
FT                                dbSNP:rs139767111).
FT                                {ECO:0000269|PubMed:10807691}.
FT                                /FTId=VAR_011588.
FT   VARIANT     121    121       A -> G (in HNSCC; dbSNP:rs121909237).
FT                                {ECO:0000269|PubMed:11801303}.
FT                                /FTId=VAR_018103.
FT   VARIANT     121    121       A -> P (in glioblastoma; loss of
FT                                phosphatase activity towards
FT                                Ins(1,3,4,5)P4).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9331071}.
FT                                /FTId=VAR_026259.
FT   VARIANT     123    123       H -> R (in CWS1; dbSNP:rs121909222).
FT                                {ECO:0000269|PubMed:10234502,
FT                                ECO:0000269|PubMed:9259288}.
FT                                /FTId=VAR_007463.
FT   VARIANT     123    123       H -> Y (in endometrial cancer; loss of
FT                                protein phosphatase activity;
FT                                dbSNP:rs786204931).
FT                                {ECO:0000269|PubMed:9256433}.
FT                                /FTId=VAR_026260.
FT   VARIANT     124    124       C -> R (in CWS1; dbSNP:rs121909223).
FT                                {ECO:0000269|PubMed:10234502,
FT                                ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9259288}.
FT                                /FTId=VAR_007464.
FT   VARIANT     124    124       C -> S (in CWS1; phosphatase-dead protein
FT                                with neither lipid nor protein
FT                                phosphatase activity).
FT                                {ECO:0000269|PubMed:11230179,
FT                                ECO:0000269|PubMed:9811831}.
FT                                /FTId=VAR_018104.
FT   VARIANT     126    126       A -> G (in a patient with prostate
FT                                cancer; reduced phosphatase activity
FT                                towards PtdIns(3,4,5); shifts its
FT                                activity from phosphatidylinositol
FT                                phosphate 3-phosphatase to
FT                                phosphatidylinositol phosphate 5-
FT                                phosphatase; disrupts PI3K/ATK signaling;
FT                                reduced cell migration).
FT                                {ECO:0000269|PubMed:26504226}.
FT                                /FTId=VAR_076551.
FT   VARIANT     129    129       G -> E (in CWS1; no lipid phosphatase
FT                                activity but retains protein phosphatase
FT                                activity; retains ability to inhibit
FT                                focal adhesion formation;
FT                                dbSNP:rs121909218).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:11230179,
FT                                ECO:0000269|PubMed:9140396,
FT                                ECO:0000269|PubMed:9616126,
FT                                ECO:0000269|PubMed:9811831}.
FT                                /FTId=VAR_007465.
FT   VARIANT     129    129       G -> R (in glioblastoma; severely reduced
FT                                protein phosphatase activity; loss of
FT                                phosphatase activity towards
FT                                Ins(1,3,4,5)P4; dbSNP:rs786204929).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9072974,
FT                                ECO:0000269|PubMed:9256433,
FT                                ECO:0000269|PubMed:9331071}.
FT                                /FTId=VAR_007466.
FT   VARIANT     130    130       R -> G (loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P4 and
FT                                PtdIns(3,4,5)P3; dbSNP:rs121909224).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026261.
FT   VARIANT     130    130       R -> L (in CWS1 and endometrial
FT                                hyperplasia; loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P4; retains ability
FT                                to bind phospholipid membranes).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9635567}.
FT                                /FTId=VAR_007467.
FT   VARIANT     130    130       R -> Q (in CWS1; loss of phosphatase
FT                                activity towards Ins(1,3,4,5)P4; retains
FT                                ability to bind phospholipid membranes;
FT                                dbSNP:rs121909229).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9915974}.
FT                                /FTId=VAR_007468.
FT   VARIANT     131    131       T -> I (in MCEPHAS; dbSNP:rs397514560).
FT                                {ECO:0000269|PubMed:23160955}.
FT                                /FTId=VAR_076762.
FT   VARIANT     132    132       G -> V (in one patient with clinical
FT                                findings suggesting hamartoma tumor
FT                                syndrome; dbSNP:rs121909241).
FT                                {ECO:0000269|PubMed:16752378}.
FT                                /FTId=VAR_032635.
FT   VARIANT     133    133       V -> I (loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P3).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026262.
FT   VARIANT     134    134       M -> L (in prostate cancer; no effect on
FT                                protein phosphatase activity; reduced
FT                                phosphatase activity towards
FT                                Ins(1,3,4,5)P3 but retains
FT                                PtdIns(3,4,5)P3 phosphatase activity).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9072974,
FT                                ECO:0000269|PubMed:9256433}.
FT                                /FTId=VAR_007469.
FT   VARIANT     135    135       I -> V (in BRRS; dbSNP:rs587782360).
FT                                {ECO:0000269|PubMed:10400993,
FT                                ECO:0000269|PubMed:11494117}.
FT                                /FTId=VAR_008736.
FT   VARIANT     136    136       C -> Y (in CWS1; loss of phosphatase
FT                                activity towards Ins(1,3,4,5)P3;
FT                                dbSNP:rs786204859).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9735393}.
FT                                /FTId=VAR_007808.
FT   VARIANT     137    137       A -> AN (in CWS1).
FT                                {ECO:0000269|PubMed:9345101}.
FT                                /FTId=VAR_008737.
FT   VARIANT     155    155       Y -> C (in CWS1; loss of phosphatase
FT                                activity towards Ins(1,3,4,5)P4).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026263.
FT   VARIANT     158    158       V -> L (in multiple cancers).
FT                                {ECO:0000269|PubMed:10807691}.
FT                                /FTId=VAR_011589.
FT   VARIANT     165    165       G -> E (in CWS1).
FT                                {ECO:0000269|PubMed:10234502}.
FT                                /FTId=VAR_008739.
FT   VARIANT     165    165       G -> R (in glioblastoma; severely reduced
FT                                protein phosphatase activity; loss of
FT                                phosphatase activity towards
FT                                Ins(1,3,4,5)P4; retains ability to bind
FT                                phospholipid membranes).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9256433,
FT                                ECO:0000269|PubMed:9331071}.
FT                                /FTId=VAR_026264.
FT   VARIANT     165    165       G -> V (in CWS1; dbSNP:rs786204863).
FT                                /FTId=VAR_008738.
FT   VARIANT     167    167       T -> N (in MCEPHAS; dbSNP:rs397514559).
FT                                {ECO:0000269|PubMed:23160955}.
FT                                /FTId=VAR_076763.
FT   VARIANT     167    167       T -> P (in breast cancer; severely
FT                                reduced protein phosphatase activity).
FT                                {ECO:0000269|PubMed:9256433}.
FT                                /FTId=VAR_026265.
FT   VARIANT     170    170       S -> N (loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P4; retains ability
FT                                to bind phospholipid membranes).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026266.
FT   VARIANT     170    170       S -> R (in BRRS; severely reduced protein
FT                                phosphatase activity; loss of phosphatase
FT                                activity towards Ins(1,3,4,5)P4;
FT                                dbSNP:rs121909221).
FT                                {ECO:0000269|PubMed:10400993,
FT                                ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:11494117,
FT                                ECO:0000269|PubMed:9241266,
FT                                ECO:0000269|PubMed:9256433}.
FT                                /FTId=VAR_007470.
FT   VARIANT     173    173       R -> C (in endometrial hyperplasia; loss
FT                                of phosphatase activity towards
FT                                Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3;
FT                                retains ability to bind phospholipid
FT                                membranes; dbSNP:rs121913293).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9635567}.
FT                                /FTId=VAR_026267.
FT   VARIANT     173    173       R -> H (loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P4;
FT                                dbSNP:rs121913294).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026268.
FT   VARIANT     173    173       R -> P (loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P4;
FT                                dbSNP:rs121913294).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026269.
FT   VARIANT     174    174       Y -> N (loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P4;
FT                                dbSNP:rs587782316).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026270.
FT   VARIANT     191    191       V -> A (in endometrial hyperplasia).
FT                                {ECO:0000269|PubMed:9635567}.
FT                                /FTId=VAR_026271.
FT   VARIANT     217    217       V -> I (in malignant melanoma; somatic
FT                                mutation; dbSNP:rs121909234).
FT                                {ECO:0000269|PubMed:10978354}.
FT                                /FTId=VAR_018105.
FT   VARIANT     227    227       S -> F (reduced phosphatase activity
FT                                towards Ins(1,3,4,5)P4 but retains
FT                                PtdIns(3,4,5)P3 phosphatase activity).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026272.
FT   VARIANT     234    234       R -> Q (in GLM2; the patient also
FT                                suffered from benign meningioma; not
FT                                capable of inducing apoptosis; induced
FT                                increased cell proliferation; led to high
FT                                constitutive AKT1 activation which could
FT                                not be increased further by stimulation
FT                                with insulin; dbSNP:rs121909235).
FT                                {ECO:0000269|PubMed:12085208}.
FT                                /FTId=VAR_018106.
FT   VARIANT     241    241       F -> S (in MCEPHAS; dbSNP:rs121909240).
FT                                {ECO:0000269|PubMed:15805158}.
FT                                /FTId=VAR_032636.
FT   VARIANT     246    246       P -> L (in BRRS; dbSNP:rs587782350).
FT                                {ECO:0000269|PubMed:10400993}.
FT                                /FTId=VAR_008740.
FT   VARIANT     251    251       G -> C (loss of phosphatase activity
FT                                towards Ins(1,3,4,5)P4; retains ability
FT                                to bind phospholipid membranes).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026273.
FT   VARIANT     252    252       D -> G (in MCEPHAS; dbSNP:rs121909239).
FT                                {ECO:0000269|PubMed:15805158}.
FT                                /FTId=VAR_032637.
FT   VARIANT     289    289       K -> E (in CWS1; reduced phosphatase
FT                                activity towards Ins(1,3,4,5)P4; retains
FT                                ability to bind phospholipid membranes;
FT                                predominantly nuclear;
FT                                dbSNP:rs562015640).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:18716620,
FT                                ECO:0000269|PubMed:9797362}.
FT                                /FTId=VAR_008741.
FT   VARIANT     290    290       V -> L (in dbSNP:rs35600253).
FT                                {ECO:0000269|Ref.10}.
FT                                /FTId=VAR_025167.
FT   VARIANT     319    319       Missing (in glioma; reduced tumor
FT                                suppressor activity; fails to inactivate
FT                                AKT/PKB). {ECO:0000269|PubMed:10468583,
FT                                ECO:0000269|PubMed:9090379}.
FT                                /FTId=VAR_026274.
FT   VARIANT     331    331       D -> G (in CWS1; reduced phosphatase
FT                                activity towards Ins(1,3,4,5)P4; retains
FT                                ability to bind phospholipid membranes).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026275.
FT   VARIANT     341    341       F -> V (in CWS1; loss of phosphatase
FT                                activity towards Ins(1,3,4,5)P4).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026276.
FT   VARIANT     342    342       K -> N (in CWS1; reduced phosphatase
FT                                activity towards Ins(1,3,4,5)P4 but
FT                                PtdIns(3,4,5)P3 phosphatase activity is
FT                                similar to wild-type; dbSNP:rs398123314).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026277.
FT   VARIANT     343    343       V -> E (in CWS1; loss of phosphatase
FT                                activity towards Ins(1,3,4,5)P4).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9399897}.
FT                                /FTId=VAR_008742.
FT   VARIANT     345    345       L -> Q (in glioblastoma; reduced tumor
FT                                suppressor activity; loss of phosphatase
FT                                activity towards Ins(1,3,4,5)P4; reduced
FT                                ability to inactivate AKT/PKB; retains
FT                                ability to bind phospholipid membranes).
FT                                {ECO:0000269|PubMed:10468583,
FT                                ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9331071}.
FT                                /FTId=VAR_026278.
FT   VARIANT     347    347       F -> L (in CWS1; reduced phosphatase
FT                                activity towards Ins(1,3,4,5)P4).
FT                                {ECO:0000269|PubMed:10866302,
FT                                ECO:0000269|PubMed:9399897}.
FT                                /FTId=VAR_008743.
FT   VARIANT     348    348       T -> I (in endometrial hyperplasia;
FT                                reduced phosphatase activity towards
FT                                PtdIns(3,4,5)P3; mildly reduced tumor
FT                                suppressor activity; reduced ability to
FT                                inactivate AKT/PKB).
FT                                {ECO:0000269|PubMed:10468583,
FT                                ECO:0000269|PubMed:9635567}.
FT                                /FTId=VAR_026279.
FT   VARIANT     369    369       V -> G (retains Ins(1,3,4,5)P4 and
FT                                PtdIns(3,4,5)P3 phosphatase activity;
FT                                retains ability to bind phospholipid
FT                                membranes).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026280.
FT   VARIANT     401    401       T -> I (retains Ins(1,3,4,5)P4 and
FT                                PtdIns(3,4,5)P3 phosphatase activity;
FT                                retains ability to bind phospholipid
FT                                membranes).
FT                                {ECO:0000269|PubMed:10866302}.
FT                                /FTId=VAR_026281.
FT   MUTAGEN       1      1       M->I: Expression is restricted to isoform
FT                                alpha. {ECO:0000269|PubMed:24768297}.
FT   MUTAGEN      13     13       K->E: Nuclear. Cytoplasmic; when
FT                                associated with E-289. Shows less tumor
FT                                suppressive ability; when associated with
FT                                E-289. {ECO:0000269|PubMed:18716620}.
FT   MUTAGEN      92     92       D->A: 700-fold reduction in phosphatase
FT                                activity towards PtdIns(3,4,5)P3. Loss of
FT                                protein phosphatase activity. Unable to
FT                                inhibit focal adhesion formation.
FT                                {ECO:0000269|PubMed:10555148,
FT                                ECO:0000269|PubMed:9616126}.
FT   MUTAGEN      93     93       H->A: 75% reduction in phosphatase
FT                                activity towards PtdIns(3,4,5)P3. Modest
FT                                reduction in phosphatase activity towards
FT                                PtdIns(3,4)P2.
FT                                {ECO:0000269|PubMed:10555148}.
FT   MUTAGEN     124    124       C->A: Loss of protein phosphatase
FT                                activity. Unable to inhibit focal
FT                                adhesion formation.
FT                                {ECO:0000269|PubMed:9616126}.
FT   MUTAGEN     125    125       K->M: Reduced phosphatase activity
FT                                towards PtdIns(3,4,5)P3, PtdIns(3,4)P2
FT                                and PtdIns(3)P.
FT                                {ECO:0000269|PubMed:10555148}.
FT   MUTAGEN     126    126       A->P: Does not reduce phosphatase
FT                                activity towards PtdIns(3,4,5)P3 and
FT                                PtdIns(3,4)P2.
FT                                {ECO:0000269|PubMed:26504226}.
FT   MUTAGEN     126    126       A->S: Does not reduce phosphatase
FT                                activity towards PtdIns(3,4,5)P3 and
FT                                PtdIns(3,4)P2.
FT                                {ECO:0000269|PubMed:26504226}.
FT   MUTAGEN     126    126       A->V: Does not reduce phosphatase
FT                                activity towards PtdIns(3,4,5)P3 and
FT                                PtdIns(3,4)P2.
FT                                {ECO:0000269|PubMed:26504226}.
FT   MUTAGEN     128    128       K->M: 85% reduction in phosphatase
FT                                activity towards PtdIns(3,4,5)P3.
FT                                {ECO:0000269|PubMed:10555148}.
FT   MUTAGEN     128    128       K->R: Does not reduce phosphatase
FT                                activity towards PtdIns(3,4,5)P3.
FT                                {ECO:0000269|PubMed:10555148}.
FT   MUTAGEN     130    130       R->M: Does not affect the ability to
FT                                inhibit AKT/PKB activation.
FT                                {ECO:0000269|PubMed:9811831}.
FT   MUTAGEN     167    167       T->A,D: 60% reduction in phosphatase
FT                                activity towards PtdIns(3,4,5)P3.
FT                                {ECO:0000269|PubMed:10555148}.
FT   MUTAGEN     171    171       Q->A,E: 75% reduction in phosphatase
FT                                activity towards PtdIns(3,4,5)P3.
FT                                {ECO:0000269|PubMed:10555148}.
FT   MUTAGEN     263    269       KMLKKDK->AAGAADA: Reduces the growth
FT                                suppression activity and cells show
FT                                anchorage-independent growth. Reduces
FT                                binding to phospholipid membranes in
FT                                vitro. Phosphatase activity towards
FT                                PtdIns(3,4,5)P3 is not affected.
FT                                {ECO:0000269|PubMed:10555148}.
FT   MUTAGEN     289    289       K->E: Cytoplasmic; when associated with
FT                                E-13. Shows less tumor suppressive
FT                                ability; when associated with E-13.
FT                                {ECO:0000269|PubMed:18716620}.
FT   MUTAGEN     327    335       KANKDKANR->AAGADAANA: Reduces growth
FT                                suppression activity and promotes
FT                                anchorage-independent growth. Reduces
FT                                binding to phospholipid membranes in
FT                                vitro; phosphatase activity towards
FT                                PtdIns(3,4,5)P3 is not affected.
FT                                {ECO:0000269|PubMed:10555148}.
FT   MUTAGEN     336    336       Y->F: Significantly lower phosphatase
FT                                activity, reduced protein stability and
FT                                decreased growth-inhibitory effect.
FT                                {ECO:0000269|PubMed:19345329}.
FT   MUTAGEN     366    366       T->A: Decreased stability.
FT                                {ECO:0000269|PubMed:20940307}.
FT   MUTAGEN     370    370       S->A: Decreased stability.
FT                                {ECO:0000269|PubMed:20940307}.
FT   MUTAGEN     401    401       T->A: Loss of DLG1-binding. No effect on
FT                                MAGI2- and MAST2-binding.
FT   MUTAGEN     402    402       K->A: No effect on MAGI2-, MAST2- and
FT                                DLG1-binding.
FT   MUTAGEN     402    402       K->W: Loss of DLG1-, MAGI2-, MAGI3- and
FT                                MAST2-binding. Decrease of protein
FT                                stability.
FT   MUTAGEN     403    403       V->A: Loss of DLG1-, MAGI2-, MAGI3-,
FT                                MAST1-, MAST2- and MAST3-binding.
FT                                {ECO:0000269|PubMed:15951562}.
FT   TURN         19     22       {ECO:0000244|PDB:1D5R}.
FT   STRAND       23     29       {ECO:0000244|PDB:1D5R}.
FT   STRAND       32     35       {ECO:0000244|PDB:1D5R}.
FT   STRAND       39     41       {ECO:0000244|PDB:1D5R}.
FT   STRAND       44     47       {ECO:0000244|PDB:5BZZ}.
FT   HELIX        50     60       {ECO:0000244|PDB:1D5R}.
FT   STRAND       61     63       {ECO:0000244|PDB:1D5R}.
FT   STRAND       65     73       {ECO:0000244|PDB:1D5R}.
FT   HELIX        78     80       {ECO:0000244|PDB:5BZZ}.
FT   STRAND       81     83       {ECO:0000244|PDB:5BZZ}.
FT   STRAND       85     90       {ECO:0000244|PDB:1D5R}.
FT   HELIX        98    100       {ECO:0000244|PDB:1D5R}.
FT   HELIX       101    112       {ECO:0000244|PDB:1D5R}.
FT   TURN        113    115       {ECO:0000244|PDB:1D5R}.
FT   STRAND      118    123       {ECO:0000244|PDB:1D5R}.
FT   STRAND      125    128       {ECO:0000244|PDB:1D5R}.
FT   HELIX       129    141       {ECO:0000244|PDB:1D5R}.
FT   HELIX       148    159       {ECO:0000244|PDB:1D5R}.
FT   STRAND      161    163       {ECO:0000244|PDB:1D5R}.
FT   HELIX       169    184       {ECO:0000244|PDB:1D5R}.
FT   STRAND      192    202       {ECO:0000244|PDB:1D5R}.
FT   STRAND      206    209       {ECO:0000244|PDB:5BZZ}.
FT   STRAND      213    219       {ECO:0000244|PDB:1D5R}.
FT   STRAND      222    226       {ECO:0000244|PDB:1D5R}.
FT   STRAND      232    235       {ECO:0000244|PDB:1D5R}.
FT   STRAND      238    259       {ECO:0000244|PDB:1D5R}.
FT   STRAND      262    264       {ECO:0000244|PDB:5BZZ}.
FT   STRAND      268    276       {ECO:0000244|PDB:1D5R}.
FT   HELIX       277    279       {ECO:0000244|PDB:1D5R}.
FT   STRAND      280    284       {ECO:0000244|PDB:5BZZ}.
FT   STRAND      310    312       {ECO:0000244|PDB:5BZX}.
FT   STRAND      315    321       {ECO:0000244|PDB:1D5R}.
FT   HELIX       322    324       {ECO:0000244|PDB:1D5R}.
FT   HELIX       328    330       {ECO:0000244|PDB:1D5R}.
FT   STRAND      335    337       {ECO:0000244|PDB:1D5R}.
FT   STRAND      342    349       {ECO:0000244|PDB:1D5R}.
FT   STRAND      395    403       {ECO:0000244|PDB:2KYL}.
SQ   SEQUENCE   403 AA;  47166 MW;  75F97C3DD6802BA9 CRC64;
     MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK
     HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA
     AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY
     LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY
     FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI
     DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS
     SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKV
//
